Hard to Treat Diseases HTDS Stock
Hard to Treat Diseases Price Chart
Hard to Treat Diseases HTDS Financial and Trading Overview
Hard to Treat Diseases stock price | 0.0000 USD |
Previous Close | 1.0E-5 USD |
Open | 1.0E-5 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 1.0E-5 - 1.0E-5 USD |
52 Week Range | 1.0E-5 - 1.0E-5 USD |
Volume | 5K USD |
Avg. Volume | 79 USD |
Market Cap | 54.82K USD |
Beta (5Y Monthly) | 9.083802 |
PE Ratio (TTM) | Infinity |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
HTDS Valuation Measures
Enterprise Value | 306.74K USD |
Trailing P/E | Infinity |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.008901644 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 0.05 |
Enterprise Value/EBITDA | 0.299 |
Trading Information
Hard to Treat Diseases Stock Price History
Beta (5Y Monthly) | 9.083802 |
52-Week Change | 0% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.0E-5 USD |
52 Week Low | 1.0E-5 USD |
50-Day Moving Average | 1.0E-5 USD |
200-Day Moving Average | 1.0E-5 USD |
HTDS Share Statistics
Avg. Volume (3 month) | 79 USD |
Avg. Daily Volume (10-Days) | 500 USD |
Shares Outstanding | 5.48B |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.025% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2009 |
Most Recent Quarter (mrq) | September 30, 2010 |
Next Fiscal Year End | December 31, 2010 |
Profitability
Profit Margin | 15.82% |
Operating Margin (ttm) | 15.94% |
Gross Margin | 28.94% |
EBITDA Margin | 16.64% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 6.16M USD |
Revenue Per Share (ttm) | 0.001 USD |
Quarterly Revenue Growth (yoy) | 5.70% |
Gross Profit (ttm) | 1.42M USD |
EBITDA | 1.03M USD |
Net Income Avi to Common (ttm) | 974.3K USD |
Diluted EPS (ttm) | 0 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 202.9K USD |
Total Cash Per Share (mrq) | 0 USD |
Total Debt (mrq) | 450.45K USD |
Total Debt/Equity (mrq) | 20.63 USD |
Current Ratio (mrq) | 2.265 |
Book Value Per Share (mrq) | 0 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.03M USD |
Levered Free Cash Flow (ttm) | N/A |
Profile of Hard to Treat Diseases
Country | United States |
State | N/A |
City | Shenzhen |
Address | Room EF, 12F |
ZIP | 518040 |
Phone | 86 755 8272 0498 |
Website | https://www.mellowhope.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
Q&A For Hard to Treat Diseases Stock
What is a current HTDS stock price?
Hard to Treat Diseases HTDS stock price today per share is 0.0000 USD.
How to purchase Hard to Treat Diseases stock?
You can buy HTDS shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Hard to Treat Diseases?
The stock symbol or ticker of Hard to Treat Diseases is HTDS.
Which industry does the Hard to Treat Diseases company belong to?
The Hard to Treat Diseases industry is Biotechnology.
How many shares does Hard to Treat Diseases have in circulation?
The max supply of Hard to Treat Diseases shares is 0.
What is Hard to Treat Diseases Price to Earnings Ratio (PE Ratio)?
Hard to Treat Diseases PE Ratio is now.
What was Hard to Treat Diseases earnings per share over the trailing 12 months (TTM)?
Hard to Treat Diseases EPS is 0 USD over the trailing 12 months.
Which sector does the Hard to Treat Diseases company belong to?
The Hard to Treat Diseases sector is Healthcare.